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Abstract 
Telomerase is a complex holoenzyme able to elongate telomere ends that have been shortened 
during successive cycles of cell division. Expression of telomerase reverse transcriptase gene 
(TERT), which is fundamental for the maintenance of telomeres length, is usually absent in 
somatic cells, but present in the majority of cancer cells and immortalized cells. MNS16A, a 
polymorphic tandem repeats minisatellite is located downstream of exon 16 of the TERT 
gene, within a promoter region of a TERT antisense transcript. MNS16A genotypes were 
determined by PCR amplification followed by electrophoretical separation in 2.5% agarose 
gels. Multiple logistic regression analysis was performed in the R programming environment. 
The aim of my diploma thesis was to assess the role of MNS16A as a potential biomarker for 
the risk of developing prostate cancer for the first time as well as for lung cancer. The prostate 
cancer study population comprised 1787 participants, composed of 1137 newly diagnosed 
prostate cancer cases and 650 controls with benign prostate hyperplasia (BPH). A strength of 
our prostate cancer study was, that controls underwent biopsy of the prostate and were 
therefore attested to be free of prostate cancer. No significant associations were observed in 
the overall study population, however, in the stratified analysis of the prostate cancer cohort, 
the MNS16A variable number of tandem repeats (VNTR)-274 was associated with a 
decreased risk of prostate cancer in men aged 70 or older (p= 0.023).  
Additionally, MNS16A was investigated as a biomarker for the risk of lung cancer based on a 
study population of 3167 participants. The lung cancer patients (n= 619) were classified 
according to their histological subtype in a small cell lung cancer (SCLC=125) and a non-
small cell lung cancer (NSCLC=476) subgroup. No significant associations were observed in 
the overall lung cancer study population. In the stratified analysis, genotype 243/302 was 
associated with a reduced risk of lung cancer in subjects aged 70 or older (p= 0.045). 
However, in subjects aged 55 or younger the genotypes 243/302 and 274/302 and the single 
MNS16A VNTR-243 were associated with an elevated risk of lung cancer (p= 0.007-0.038). 
In the subgroup of  NSCLC patients, genotypes 243/302 and 302/333 and single VNTR-243 
were associated with a reduced NSCLC risk in subjects aged 70 and older (p= 0.012-0.046), 
which is in accordance with the results of the very first MNS16A study, published by Wang et 
al. in 2003. In subjects aged 55 and younger, the genotypes 243/302 and 274/302 and the 
single VNTR-243 were associated with an increased risk of  NSCLC (p= 0.006-0.03).  
Five VNTRs of MNS16A are known so far and termed according to their PCR fragment size. 
In the course of my diploma thesis a novel MNS16A allele was identified, namelyVNTR-212, 
the shortest VNTR that has been identified so far. 
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Although further investigations in larger cohorts are required to establish MNS16A as a 
possible biomarker for the risk assessment of prostate cancer and lung cancer, this diploma 
thesis has given several significant associations of MNS16A variants and the risk of prostate 
cancer and lung cancer.                                                                                                             
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Zusammenfassung 
Telomerase ist ein komplexes Holoenzym, das in der Lage ist, Telomere, welche sich durch 
Zellteilung stetig verkürzen, zu verlängern. Das Gen Telomerase reverse Transkriptase 
(TERT), wird normalerweise in somatischen Zellen nicht exprimiert, wohl aber in der 
Mehrheit von Krebs- bzw. immortalen Zellen. 
MNS16A, ein polymorpher „tandem repeats“ Minisatellit, ist „downstream“ von Exon 16 
lokalisiert und liegt innerhalb einer Promoter Region eines TERT Antisense- Transkripts. Die 
MNS16A Genotypen wurden durch PCR Amplifikation und anschließender Separation in 
2,5%igen Agarose Gelen bestimmt. Multiple logistische Regressionsanalysen wurden im 
Programm „R“ durchgeführt.  
Ziel dieser Arbeit war es, zu untersuchen, ob MNS16A ein geeigneter Biomarker für 
Prostatakarzinomrisiko als auch Lungenkarzinomrisiko sein könnte. Die Studienpopulation 
der Prostatakarzinomstudie bestand insgesamt aus 1787 Teilnehmern, davon 1137 Patienten 
mit neu diagnostiziertem Prostatakarzinom und 650 Kontrollpatienten mit benigner 
Prostatahyperplasie (BPH). In der gesamten Studienpopulation konnten keine statistisch 
signifikanten Assoziationen beobachtet werden. Jedoch wurde in einer stratifizierten Analyse 
das MNS16A „variable number of tandem repeats“ (VNTR)-274 mit einem reduzierten 
Prostatakrebsrisiko bei Männern in einer Altersklasse von 70 Jahren oder älter signifikant 
assoziiert (p=0,023).  
Die Lungenkarzinom Studienpopulation bestand aus 3167 Teilnehmern. Patienten mit 
Lungenkarzinom (n=619) bestanden ihrem histologischen Subtyp entsprechend, aus 125 
Patienten mit kleinzelligem Lungenkarzinom (SCLC) und 476 Patienten mit nicht-
kleinzelligem Lungenkarzinom (NSCLC). In der gesamten Studienpopulation konnten keine 
statistisch signifikanten Assoziationen beobachtet werden. In einer stratifizierten Analyse 
wurde bei Teilnehmern von 70 Jahren oder älter ein signifikanter Zusammenhang zwischen 
dem Genotyp 243/302 und einem reduzierten Lungenkrebsrisiko beobachtet (p= 0,045). Bei 
Männern von 55 Jahren oder jünger konnten die Genotypen 243/302 und 274/302 und das 
MNS16A VNTR-243 mit einem erhöhten Lungenkrebsrisiko assoziiert werden (p= 0,007-
0,038). In der NSCLC Untergruppe der ≥70 Jährigen wurden die Genotypen 243/302 und 
302/333 und VNTR-243 mit einem reduziertem NSCLC Risiko assoziiert (p= 0,012-0,046), 
was mit den Ergebnissen der ersten MNS16A Studie von Wang et al. im Jahre 2003 
übereinstimmt. In der Untergruppe der ≤55 Jährigen konnten die Genotypen 243/302 und 
274/302 und VNTR-243 mit einem erhöhten NSCLC Risiko assoziiert werden (p= 0,006-
0,03).  
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Bisher waren fünf VNTRs, die nach der Größe ihrer PCR Fragmente benannt wurden, 
bekannt. Im Rahmen meiner Diplomarbeit wurde eine weitere MNS16A Variante, VNTR-
212, die bislang kürzeste Variante entdeckt. 
Obwohl noch weitere Untersuchungen in größeren Studienpopulationen nötig sind, um 
MNS16A als möglichen Biomarker für die Risikobeurteilung von Prostatakrebs und 
Lungenkrebs zu etablieren, konnten in dieser Diplomarbeit signifikante Assoziationen 
zwischen MNS16A Varianten und dem Risiko von Prostata- und Lungenkrebs beobachtet 
werden.   
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1. Introduction 
1.1. Epidemiology 
1.1.1. Epidemiology of prostate cancer 
1.1.1.1. Epidemiology of prostate cancer worldwide  
Prostate cancer is the second most frequently diagnosed cancer in male patients worldwide, 
comprising 13.6% of the total cancer cases and 6.1% of the total cancer deaths in men. 
Incidence rates for prostate cancer can vary up to 25fold worldwide, with Australia/New 
Zealand having the highest incidence rate for prostate cancer, followed by western and 
northern Europe and northern America. Particularly high incidence rates occur among African 
Americans, the lowest incidence rates worldwide are recorded in south-east Asia. In 2008, 
around 900.000 men were diagnosed with prostate cancer worldwide ,(Globocan/a, 2008) 
382.300 of them were recorded in Europe (Ferlay et al., 2010). The high prostate cancer 
incidence in Western countries is associated with the implementation of large-scale prostate 
cancer screening programs (Sakr et al., 1996). By this measure, mortality due to prostate 
cancer was significantly reduced (Hugosson et al., 2010; Jemal et al., 2005; Schroder et al., 
2009), since a greater proportion of men were diagnosed with prostate cancer in an early stage 
of their disease, referred to as “stage migration” (Cooperberg et al., 2003). The amount of 
patients presented with distant metastases at time of diagnosis was reduced from 16 to 4% 
with screening, as reviewed in (Tosoian and Loeb, 2010). Anyway, screening for prostate 
cancer leads to the key aspect of over-diagnosis, followed by over-treatment of clinically 
insignificant cancers, which is assumed to be as much as 50% (Draisma et al., 2003). Men 
with an indolent prostate cancer would not require radical treatment, like surgery, and may 
suffer from side effects, like erectile dysfunction and incontinence, wherefore the cost-benefit 
ratio of surgery versus active surveillance must be considered (Marberger et al., 2012).  
The mortality ratio for prostate cancer varies about 10fold worldwide, the highest mortality 
occurs in primarily black populations, the lowest mortality rates occur in Asia. In 2008, 
roughly 260.000 deaths due to prostate cancer were recorded worldwide, around 70.000 of 
them occurred in Europe (Globocan/a, 2008).  
 
1.1.1.2. Epidemiology of prostate cancer in Austria 
In Austria, prostate cancer is the leading cancer site in males, accounting for 26.4% of the 
total new cancer cases. It is the third leading cause of death among Austrian men with 11.3% 
of all cancer deaths following lung and colorectal cancer deaths.  
In 2009 almost 4.900 patients have been diagnosed of prostate cancer, which is in strong 
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contrast to 1989, when 2.317 cases of prostate cancer were reported only . The increased 
incidence rate is associated with the widespread prostate cancer screening programs, 
conducted particularly in Western regions of Austria. Although a gradual decline in prostate 
cancer incidence was observed in Austria since 2003 this trend might largely be attributed to 
the earlier identification of prostate cancer, including non-symptomatic indolent prostate 
cancer.  
Prostate cancer related mortality lessened from 21.9/100.000 men in 1989 to 15/100.000 men 
in 2009, due to the introduction of prostate cancer detection programs and improved curative 
treatment (Hugosson et al., 2010; Jemal et al., 2005; Schroder et al., 2009). The cumulative 
risk to develop prostate cancer before the age of 75 was in 2009 reduced to 9%, the 
cumulative risk to die from prostate cancer dropped to 0.7% (Statistik-Austria/a, 2009).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1.1.3. Risk factors for prostate cancer 
One of the most significant risk factors for the development of prostate cancer is advanced 
age. Only 0.6% of all prostate cancer cases arise in men younger than 45 years, whereas it is 
between 62% and 85% after the age of 65 (Fournier et al., 2004). According to the US 
Surveillance, Epidemiology and End Results Program (SEER), the incidence rate of prostate 
cancer, recorded between 2000 and 2008, rises from 9.2/100.000 for men aged 40-44 to 
984.8/100.000 for men aged 70-74, as reviewed in (Leitzmann and Rohrmann, 2012). Since 
-
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Figure 1:  Statistik Austria a.; Incidence and mortality of prostate cancer in Austria 
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androgens affect the development and growth of the prostate gland, testosterone is considered 
to be an important determinant for the occurrence of prostate cancer. Increased levels of 
circulating testosterone combined with low levels of sex hormone-binding globulin (SHBG) 
(both within an endogenous range) were associated with an elevated risk of prostate cancer 
(Gann et al., 1996).  
Furthermore, ethnicity varies the risk of developing prostate cancer. Men of African descent 
have a 1.6fold higher incidence rate of prostate cancer compared to the Caucasian population 
(Leitzmann and Rohrmann, 2012). A positive family history of prostate cancer is another risk 
factor for its occurrence. According to the Swedish Family Cancer Database, 20.2% of men 
diagnosed with cancer before the age of 72 have a paternal or fraternal cancer history. The 
risk of developing prostate cancer rises with the amount of first degree relatives, diagnosed 
with prostate cancer (Figure 2) (Hemminki, 2011). Family-based linkage studies, twin studies 
and molecular epidemiology studies provided evidence that genetics play a key role in the 
development of prostate cancer. It is estimated, that 42% of prostate cancer risk is possibly 
explained by genetic determinants (Lichtenstein et al., 2000).  
 
  
  
  
  
  
  
  
 
 
 
 
 
 
1.1.1.4. Screening for prostate cancer  
Prostate cancer is indicated by increased levels of prostate specific antigen (PSA) in blood 
plasma. The glycoprotein, that is encoded by the KLK3 (kallikrein related peptidase 3) gene, 
is present at a low concentration in the serum of healthy men, but elevated in men with 
prostate disorders like prostate cancer (Kuriyama et al., 1980; Papsidero et al., 1980). PSA 
Figure 2:  Hemminki 2011; prostate cancer risk and affected relatives 
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level as a biomarker, was introduced throughout the 1990s and was considered to be a tool for 
early diagnosis and monitoring of prostate cancer (Catalona et al., 1991). Unfortunately, the 
PSA test has a high false-positive rate (Etzioni, 2008). PSA screening may lead to over-
diagnosis and over-treatment of indolent tumors, possibly followed by preventable side 
effects (Marberger et al., 2012). However, PSA is the only available marker so far. Therefore, 
there is a great demand for a biomarker that enables to distinguish the aggressive from the 
indolent form of prostate cancer at the time of diagnosis. While men with aggressive tumors 
will benefit more from radical treatment, men with the indolent form profit more from 
„watchful waiting“ and can be spared from side effects of surgery.  
 
1.1.2. Epidemiology of lung cancer 
1.1.2.1. Epidemiology of lung cancer worldwide 
Before the 20th century lung cancer was a rare disease, but since then tobacco consumption 
rose rapidly and lung cancer incidences increased subsequently (Brennan et al., 2011). In 
2008 lung cancer was the third most common malignancy worldwide, accounting for 12.5% 
of all new cancer cases, and the most common cause of cancer related death with a share of 
18.2%. The highest incidence rates occur in Central- Eastern- and Southern Europe and 
Northern America, while Middle- Western- and Eastern Africa have the lowest incidence 
rates. There is also a discrepancy between lung cancer incidence and mortality in men and 
women, in ways that female cases are generally less frequent. In men lung cancer is the most 
common diagnosed kind of cancer, while in women it is placed fourth, following breast, 
cervix uteri and colorectal cancer. Regarding mortality, however, it is placed second in 
females and first in males. In Northern America, females have the highest incidence and 
mortality rates, for males it is Central and Eastern Europe. The ratio of mortality to incidence 
is 0.86, illustrating the high death rate, which is similar in every country or region 
(Globocan/b, 2008).  
 
1.1.2.2. Epidemiology of lung cancer in Austria 
In Austria, 4239 newly diagnosed lung cancer cases, accounting for 11% of all newly 
diagnosed neoplasms, were observed in 2009. Of 29 per 100.000 habitants 24 patients will die 
from lung cancer. In men, lung cancer is the second most frequently diagnosed cancer, 
following prostate cancer, but the leading cause of cancer related death. In Austrian women, 
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lung cancer is placed third regarding the incidence, only surpassed by breast and colorectal 
cancer, and placed second regarding the mortality.   
Concerning both, incidence and mortality, men account for two thirds of all cases, largely 
caused by the higher rate of male smokers. However, age standardized incidence and 
mortality rates in women increased by about 20% (23% and 20%) during the last ten years.  
Although the mortality in men slightly decreased during the last years, the overall mortality of 
lung cancer remained more or less unchanged (Figure 3). The life time risk for developing 
lung cancer, before the age of 75, accounts to 4.8% for men and 2.2% for women (Statistik-
Austria/b, 2009).  
 
 
 
 
1.1.2.3. Risk factors 
The carcinogenic impact of tobacco was first demonstrated in the 1950s, followed by 
epidemiologic studies, showing, that tobacco is the main exogenic cause of lung cancer 
(Brennan et al., 2011). Between 80 and 90% of lung cancer cases are attributed to smoking 
(Hammond and Seidman, 1980), however, only 10-15% of smokers develop lung cancer 
(Mattson et al., 1987), indicating inter-individual differences in carcinogen susceptibility 
(Schwartz et al., 2007). Except smoking and second hand smoking, exposure of 
environmental carcinogens, like asbestos or radon (Goeckenjan et al., 2011) and differences in 
susceptibility to lung cancer may contribute to the remaining lung cancer risk (Schwartz et al., 
2007). 
-
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A positive family history of lung cancer elevates the personal risk of developing the disease, 
suggesting a genetic component in lung carcinogenesis. With an affected first-degree relative 
the risk of lung cancer increases up to 9fold (Dong and Hemminki, 2001; Risch, 2001), 
determined by genetic susceptibility and/or familial clustering of environmental risk factors 
(Lorenzo Bermejo and Hemminki, 2005).  
Further, ethnicity varies the incidence rate of lung cancer, with above-average rates in Afro-
Americans and among women in certain regions of China. Again, the increased prevalence of 
lung cancer among certain ethnicities may be explained by genetic variation in susceptibility 
to lung cancer and/or by a certain behavior in dealing with carcinogens, like carcinogen 
generating cooking in certain regions of China (Brennan et al., 2011; DeMarini et al., 2001).  
1.1.2.4. Screening for lung cancer  
Lung cancer is one of most aggressive kinds of cancer with a strong tendency to metastasize 
(Petersen, 2011). In many patients, the cancer is already in an advanced state by the time they 
show characteristic symptoms (Wood et al., 2012). At time of diagnosis less than 0.1% of 
lung cancer cases are staged carcinoma in situ while the majority is already disseminated 
(27%). Lung cancer is usually diagnosed by chest X-ray and confirmed by lung biopsy. The 
5-year survival rate for males amounts 15%, for females 18%, reflecting only limited 
advances in screening and treatment (Petersen, 2011). Therefore, it is an essential issue to find 
a minimal invasive marker for early detection of lung cancer, when treatment is more likely to 
be successful (Aberle et al., 2011).  
 
1.2. Anatomy and Pathology of the prostate 
The prostate is an exocrine glandular organ located in the small pelvis, just under the bladder 
and in front of the rectum. The prostate secretes a fluid that nourishes and protects sperm and 
is squeezed into the urethra, by smooth muscle cell contraction, during ejaculation. Four 
anatomic regions of the prostate gland are described: 70% of the prostate tissue is the 
peripheral zone. It surrounds the distal urethra and prostate tumors usually originate here. The 
central zone constitutes about 25% of the gland and surrounds the ejaculation ducts. The 
remaining 5% of the prostate gland are divided in transition zone, which grows lifelong and is 
therefore typically the origin of benign prostatic enlargements, and the anterior fibromuscular 
stroma, which forms the anterior surface of prostate as a non-glandular apron (Amin et al., 
2010). The prostate comprises an epithelial and a stromal compartment, which are separated 
by the basement membrane, a barrier consisting of collagen fibers (Bonkhoff et al., 1991). 
The epithelial cell compartment is built up by two kinds of cell layers. The luminal epithelial 
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cell layer produces prostatic secretion and is completely separated from the stroma by the 
second kind of epithelial cells, the basal epithelial cells (Brawer et al., 1985). The stromal cell 
compartment consists of smooth muscle cells and myofibroblasts, which are interspersed with 
inflammatory cells, cells of the nerve system, blood vessels and lymphatics (Bartsch et al., 
1979).  
Between 70-80% of men in their 7th-8th life decade, develop a hyperplastic prostate 
epithelium, which is called benign prostate hyperplasia. It is well accepted that BPH is neither 
a premalignant lesion nor a precursor carcinoma (Gsur et al., 2000). In BPH the luminal 
epithelial cells accumulate, but stay morphologic and cytologic inconspicuously. About 10% 
of men with BPH require treatment (Bushman, 2009). In contrast to BPH, prostatic 
intraepithelial neoplasms (PIN) is considered to be a precursor to invasive prostate 
carcinomas. In PIN the luminal cells feature enlarged cell nuclei with striking nucleoli, 
further, integrity of basal epithelial cells decrease (Ayala and Ro, 2007). Usually, prostate 
carcinomas are classified as multifocal adenocarcinomas. In 80% of all cases, prostate 
carcinomas arise in the peripheral zone of the prostate gland. Characteristics of prostate 
cancerous tissues may be ramification of the glandular morphology, gland fusion, inability to 
form a lumen, attrition of the basal cell layer and nucleus enlargement attended by 
aneuploidy. If prostate cancer is in an advanced stage, metastases in bone and lymph nodes 
occur frequently (Knudsen and Vasioukhin, 2010). Tumors are classified based on the 
Gleason Score, which was introduced by the pathologist D. Gleason in 1974. This Grading 
relies on the most prevalent architectural pattern of the tumor (Gleason and Mellinger, 1974).  
 
1.3. Anatomy and Pathology of the lung 
The lung is divided in the right lung (pulmo dexter) and the left lung (pulmo sinister), which 
are further segmented in pulmonary lobes (lobi pulmonis). The left lung is more limited in 
space and consists of two lobes, whereas the right lung consists of three lobes. Lobes in turn 
are composed of bronchopulmonary segments, ten for the right side and nine for the left side. 
Air enters the lung via the bronchial system, finally the gaseous exchange happens in the 
alveoles, which are located at the end of the bronchial tree. The bronchial tubes are built up by 
ciliated epithelial cells and a subjacent layer of smooth muscles, including nestled elastic 
fibers and glands (Fanghänel J., 2003).  
Lung cancer is classified in two main types, namely small cell lung cancer (SCLC) and non-
small cell lung cancer (NSCLC). NSCLC can be further divided in Adenocarcinoma, 
Squamous cell carcinoma and Large cell carcinoma. SCLC cases account for about 20%, 
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Adenocarcinomas for 40%, Squamous cell carcinomas for 25-30% and Large cell carcinomas 
for 10-15% of all lung cancer cases. Metastases of lung cancer are primarily sited at lymph 
nodes, liver, bones, suprarenal gland and brain. Bronchial carcinomas are staged according to 
the TNM-classification system, which is based on the size of the primary tumor (T in situ- 4), 
location of afflicted lymph nodes (N0-N3) and the existence of distant metastases (M0-M1). 
Dependent on the TNM-categories, lung cancer staging is set (stage 1-stage 4), with different 
prognosis of therapeutic success (Pirker R., 1996).  
 
1.4. Molecular Epidemiology 
The term “molecular epidemiology” was introduced by Perera and Weinstein as a 
multidisciplinary approach in cancer research in 1982 (Perera and Weinstein, 1982). The 
discipline of molecular cancer epidemiology integrates advanced  molecular biology into 
traditional epidemiology, in order to unveil possible biochemical and molecular causes for 
cancer. Its aim is to elucidate the molecular events occurring between the causative exposure 
of a carcinogen and the cancer outcome, considering an individual predisposition (Vineis and 
Perera, 2007). A range of Biomarkers were integrated in molecular epidemiologic studies,  
classified as (1) markers of internal dose, (2) markers of biologically effective dose, (3) 
markers of early response/effect and (4) markers of susceptibility. The biomarker of the 
internal dose was used to measure the concentration of a suspected carcinogen to assess the 
associated personal risk. The carcinogen or its metabolites can be detected in cells, tissues or 
body fluids, even at a very low concentration, but is not predictive for any genetic alteration. 
Therefore assays have been developed to detect the biologically effective dose of an agent, 
which is interacting with critical cellular macromolecules, like DNA. The carcinogen-DNA-
adduct extent, respectively the DNA damage, mirrors the amount of incorporated carcinogens. 
It must be considered, that there is an inter-individual disparity in absorption and metabolism 
of carcinogens, as well as in repair events, regarding DNA-adducts. Beside the external 
pathway, several endogenous determinants are known, such as inflammatory processes, 
contributing to non-specific DNA damage. Markers of early biologic effects resulting from 
exposure reflect the subsequent events in carcinogenesis. They are the third kind of 
biomarkers and determine chromosomal and genetic alterations, like aberrations, deletions 
and point mutations. Some rearrangements are characteristic for an incipient, specific cancer, 
and may therefore operate as an early reporter. Biomarkers of susceptibility, the fourth 
category of biomarkers, address inherited or acquired genomic patterns, modulating the 
personal risk of developing cancer (Perera and Weinstein, 2000).  
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Biomarkers of epigenetic modification were integrated in the field of molecular 
epidemiology. The functional regulation of gene expression by epigenetic events, such as 
DNA methylation, plays a major role in carcinogenesis, induced from exposure (Kim, 2004). 
Through advanced techniques, new approaches in the establishment of biomarkers are 
available. They are fielded for identification of intermediate changes in the molecular profile 
caused by exposure, additionally they are used as an early marker for cancer onset. In 
proteomics, particular proteins or proteomic patterns within the whole protein output are 
identified and utilize as a tool to distinguish between normal and cancerous cells (Kikuchi and 
Carbone, 2007). In the field of metabolomics, the total of low-molecular weight metabolites 
present in a cell is determined, to design a personal metabolomic profile in order to evaluate 
the individual risk of cancer (Lindon et al., 2004).  
 
1.4.1. Genetic susceptibility  
Genetic influence in cancer development is an issue since linkage studies based on high-risk 
families, identified rare cancer susceptibility loci for common cancers, such as adenomatous 
polyposis coli (APC) for colorectal cancer and breast cancer gene 1/2 (BRCA1/2) in familial 
breast cancer (Bodmer et al., 1987; Hall et al., 1990; Wooster et al., 1994). Mutations in high-
risk genes, usually tumor suppressor genes, are of low frequency (<1/1000), but of high 
penetrance (Fletcher and Houlston, 2010; Hindorff et al., 2011). Mutations in high penetrance 
genes account for just a small proportion of inherited susceptibility. The remaining familial 
risk is very likely correlated with combinations of common, low to moderate penetrance 
susceptibility alleles (Pasche and Yi, 2010).  
The first approach to identify common variants of low-penetrance cancer susceptibility loci, 
was through candidate gene association studies (Gianfagna et al., 2012). Candidate genes are 
selected based on a priori hypothesis of their involvement in carcinogenic-related events, such 
as DNA repair or apoptosis, referred to as “functional candidate gene approach”. 
Additionally, genes that are often deleted or amplified in cancerous cells are investigated by 
the “positional candidate gene approach” (Imreh et al., 2003; Oldenburg et al., 2007). Initial 
candidate gene studies investigated on one polymorphism within one candidate gene, based 
on small case-control cohorts. Subsequent studies focused on more than one polymorphism in 
one single candidate gene, considering that 10-100 functional polymorphisms, especially 
single nucleotide plymorphisms (SNPs) and copy number variations (CNVs), are located 
within a 30Kb gene. Additionally, polymorphisms sited thousands of base pairs away from 
the target gene or within its introns interfere with gene expression and/or modify the splicing 
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process of the transcribed mRNA (Gianfagna et al., 2012). The identification of all 
polymorphic sites within one gene enabled to identify linkage disequilibrium (LD) relations 
between certain SNPs, condensed in Haplotypes. SNPs within one Haplotype are mutually 
correlated and are therefore characterized by tagging SNPs (tSNP). The gene-wide variation is 
more exact determined by just the merest subset of tSNPs, which are exemplary for the whole 
Haplotype, than by independent SNPs (Fallin and Schork, 2000). In 2003, researchers from 
the HapMap project came up with a validated set of haplotypes resp. tSNPs encompassing the 
whole human genome, also considering different ethnicities, that enabled to extend 
association studies from single genes to the whole genome (HapMap, 2003). In the course of 
the HapMap project, about 5 Mio SNPs were identified and further clustered according to 
their LD state. Based on this new knowledge and advanced technologies, genome wide 
association studies (GWAS) followed. The genome wide approach enabled to genotype up to 
1 Mio SNPs at once, about 10 SNPs per gene, resulting in a huge dataset. The big advantage 
of this new approach is the ability to detect functional polymorphisms, sited in unsuspected 
genomic regions of the entire genome, wherefore association studies are no longer dependent 
on a priori hypothesis of genes, potentially involved in carcinogenic events (Gianfagna et al., 
2012).  
GWAS are conducted concerning cancer risk, clinical outcome and treatment response and 
require some essentials, such as a sufficient amount of cases and controls, approved statistical 
significant levels and stratification for confounders (Miyagawa et al., 2008; Ziegler et al., 
2008). So far, about 100 cancer susceptibility polymorphisms were mapped by GWAS, with a 
low solitary effect, but due to their prevalence, with a strong common impact on cancer 
susceptibility (Figure 4) (Chanock and Hunter, 2008). Next generation sequencing, which 
supports genotyping enormous quantities of genomic DNA up to entire genomes, is the new, 
cost-effective approach in cancer research (Shendure and Ji, 2008). One such implementation 
is the sequencing of the complete human genome, as published recently (Levy et al., 2007; 
Wang et al., 2008a; Wheeler et al., 2008). Furthermore, DNA of normal and cancerous cells 
of one individual can be matched, in order to gain insights on the total genetic changes in 
carcinogenesis (Ley et al., 2008). 
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1.4.1.1.Genetic Susceptibility of prostate cancer 
Familial clustering is among the most important risk factors for prostate cancer (Simard et al., 
2002), however, unlike other malignancies, no classical high-penetrance genes have been 
identified yet (Hindorff et al., 2011). The closest candidate is BRCA2, which confers a 20fold 
increase in prostate cancer risk, compared to the general population (Edwards et al., 2003).   
Recent GWAS identified at least 40 common, low-risk (OR<2) variants on several 
chromosomes associated with prostate cancer risk, e.g. on 2p15, 8q24, 17q, 19q13, and Xp11 
(Nakagawa et al., 2012). This is the highest number among common cancers, suggesting that 
these common alleles generate the genetic influence in prostate carcinogenesis (Hindorff et 
al., 2011). The high number of functional polymorphisms may be explained by the weaker 
selection pressure, since prostate cancer occurs mostly in elder men. The cumulative impact 
of these identified loci explain at the minimum 20% of the familial risk of prostate cancer 
(Varghese and Easton, 2010). It is assumed, that the identified loci take part in the initiation of 
cancer, rather than in the progression or aggressiveness, since associations between genetic 
variants and the severity of  prostate cancer could not be determined (Witte, 2009).  
 
1.4.1.2.Genetic Susceptibility of lung cancer 
Although environmental exposure exerts the primary influence on the etiology of lung cancer, 
several genetic predispositions, modifying the risk of developing lung cancer are known. 
Lung cancer related genes are classified in rare high-risk genes (effect size >10; 1% of 
Figure 4:  Fletcher et al. 2010; Dosage effect of susceptibility alleles 
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population), moderate-risk variants (effect size=2-5; <5% of population) and common low-
risk variants (effect size =1.1-1.5; >5% of population) (Brennan et al., 2011). Family and 
linkage studies detected high-penetrance alleles of the tumor protein p53 gene (TP53), 
retinoblastoma 1 gene (RB1) and 6q23-25, which are associated with lung cancer risk 
(Fletcher et al., 2004; Hwang et al., 2003; You et al., 2009). TP53 mutation carrier have just a 
slightly higher incidence of lung cancer, compared to the general population, but the mean 
age of onset is noticeable lower (Birch et al., 2001; Olivier et al., 2003). Two genes of low to 
moderate penetrance, glutathione S transferase M1 (GSTM1) and CHEK2, have been 
identified through candidate gene studies. Individuals with a deletion in the GSTM1 gene, 
have a diminished ability to detox environmental carcinogens, whereby the risk of lung cancer 
is elevated (Shi et al., 2008; Vineis et al., 2007). Cancer of the bladder is, like lung cancer, 
strongly influenced by tobacco exposure and also associated with GSTM1-null carriers, 
supporting the role of GSTM1 as a susceptibility marker for lung cancer (Garcia-Closas et al., 
2005). However, confirmation in larger cohorts is required (Brennan et al., 2011). Rare 
variants of CHEK2, an important cell-cycle control gene with key role in the maintenance of 
cell integrity, are significantly associated with a decreased risk of lung cancer (Brennan et al., 
2007), whereas they have a contrary association with several other cancers (Cybulski et al., 
2004). The underlying mechanisms of this opposed functionality is unclear (Brennan et al., 
2011). GWAS identified three low-penetrance loci, 15q25.1, 6p21 and 5p15.33, associated 
with lung cancer, accounting for 7% of the familial risk (Varghese and Easton, 2010). The 
polymorphism at 15q25.1 varies lung cancer susceptibility, either direct (Amos et al., 2008; 
Hung et al., 2008; Thorgeirsson et al., 2008) or implicit by an enhanced nicotine dependence 
(Saccone et al., 2007). The second susceptibility locus, located at 6p21, resides within HLA 
class II region, but the functionality is little understood (Wang et al., 2008b). Furthermore, 
polymorphisms at 5p15.33, a chromosomal region containing the cleft lip and palate 
transmembrane protein 1-like protein gene (CLPTM1L) and the telomerase reverse 
transcriptase (TERT) gene, were found to be associated with lung cancer, especially with 
adenocarcinoma. All identified SNPs are intronic and residue within a region of  LD 
containing the CLPTM1L gene and the 5` end of the telomerase gene, including the TERT 
promoter. Besides SNPs, non coding minisatellites, like MNS16A, were found to modulate 
lung cancer risk dependent on the number of tandem repeats, as reviewed in (Baird, 2010). 
MNS16A is located near the telomerase gene, which is a promising hotspot in cancer 
research. 
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1.5. Telomerase 
Telomeres are stabilizing ribonucleoprotein structures at chromosome ends, preventing them 
from being recognized as DNA double strand breaks by the DNA repair machinery (Baird, 
2010). Telomerase is composed of TERT, the catalytic subunit, telomere template-containing 
RNA component (TERC), the RNA template for telomeric repeats synthesis and telomerase-
associated proteins (Cong et al., 2002).  
During cell division, synthesis of the lagging strand remains incomplete, resulting in a 
progressive shortening of telomeres, termed as end-replication problem. Each cell division 
leads to a telomere abbreviation of 25-200bp. Once telomeres become critically short, the cell 
enters p53 mediated replicative senescence, a viable but quiescent state, referred as the 
Hayflick limit (Dhaene et al., 2000). The limited replicative potential is an important tumor 
suppressor mechanism through preserving the cell from accumulation of multiple oncogenic 
mutations, cluttered during life span. It functions as a barrier against tumorigenesis (Cong et 
al., 2002). Due to mutations within the p53 pathway, critically short telomeres escape from 
the cell cycle arrest, whereby the life span is extended by around 30-40 doublings (Dhaene et 
al., 2000). Finally telomeres get ultra-short and genomic instability, telomere fusion, dicentric 
chromosomes and genomic rearrangements are the consequences (Baird, 2010). This state is 
called crisis and usually it is associated with cell death. A few cell bypass crisis through re-
activation of telomerase expression, leading to cell immortalization and unlimited 
proliferation, a necessity for cancer. Reactivated and up-regulated telomerase expression is a 
critical event in tumorigenesis, at least some immortal cells are present in most malignant 
tumors (Dhaene et al., 2000). Besides mutations in tumor-suppressor genes and proto-
oncogenes, telomerase expression is an essential requirement for a tumorigenic cell 
conversion. Around 90% of tumor samples show telomerase activity (Cong et al., 2002). The 
presence of telomerase is a useful and common tumor marker for diagnostic and prognostic 
purposes. Somatic cells, except for germ cells and cycling stem cells of self-renewing tissues, 
do not show telomerase expression (Shay and Bacchetti, 1997). Besides telomerase dependent 
lengthening of telomeres, alternative lengthening of telomeres (ALT) is capable of telomere 
stabilization (Dhaene et al., 2000). 
The limiting factor of telomerase activity is its catalytic subunit, telomerase reverse 
transcriptase, which is encoded by the TERT gene, located at 5p15.33. Up-regulation of 
telomerase in tumors is sometimes caused by the amplification of the TERT locus. In 13% of 
cancer samples the short arm of the fifth chromosome, where TERT gene is located, is 
amplified, the 5p15.33 segment is amplified frequently in many cancer types, for example in 
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early-stages of SCLC. The TERT gene is subject to a complex regulation, including 
transcriptional activators and repressors and epigenetic events, indicating that little variation 
within this area may result in an altered telomerase expression level. It is also highly 
conserved with only a slight inter-individual genetic variance, supporting the thesis, that  
variation affects telomerase activity and therefore telomere length. The 5p15.33 region also 
contains the CLPTM1L gene, which is involved in cell apoptosis, induced by cisplatin 
treatment. Multiple GWAS identified strong associations between polymorphisms within the 
TERT/CLPTM1L locus and the risk of developing basal cell cancer, pancreatic cancer and 
lung cancer. Furthermore, risk alleles, associated with bladder cancer, cervical cancer, 
prostate cancer and glioma were identified by GWAS (Baird, 2010).   
 
1.5.1. MNS16A-Polymorphism 
The polymorphic tandem repeats minisatellite MNS16A is located downstream of exon 16 of 
telomerase gene, within the promoter region of a TERT antisense transcript (indicated by red 
circle). It was first identified in 2003 by Wang et al. in the course of a lung cancer study.  The 
region of the TERT gene is rich in micro- and minisatellites, which are indicated by asterisks 
(Figure 5) (Wang et al., 2003).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The repetitive core element is composed of either a 23bp or a 26bp sequence, containing CAT 
trinucleotide insertions. These insertions operate as binding sites for the transcription factor 
GATA-1. Four variable number of tandem repeats (VNTRs) of MNS16A are known and 
Figure 5: Wang et al. 2003; TERT gene 
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termed according to their Polymerase Chain Reaction (PCR) fragment size (VNTR-243,-274,-
302,-333) (Wang et al., 2003). Recently a fifth rare MNS16A variant was identified, VNTR-
364 (Hofer et al., 2011).  
Figure 6 illustrates the wild-type allele, VNTR-302, containing five tandem repeats, indicated 
by boxes, separated by CAT inserts. VNTRs are often classified in short (S) variants (VNTR-
243,-274) and long (L) variants (VNTR-302,-333,-364).     
 
It has been shown that this functional minisatellite has a promoter activity for an hTERT 
antisense transcript that is dependent on the number tandem repeats. Shorter variants were 
shown to have a higher promoter activity suggesting a role in the repression of telomerase 
expression. This minisatellite has been investigated in the context of lung, brain, breast, 
colorectal and nasopharyngeal cancer with controversial results (Andersson et al., 2009; 
Carpentier et al., 2007; Hofer et al., 2011; Jin et al., 2011; Wang et al., 2003; Wang et al., 
2010; Wang et al., 2006; Wang et al., 2008c; Zhang et al., 2011).   
 
1.6. Aim of the study 
The aim of the present diploma thesis was to investigate whether the polymorphic tandem 
repeats minisatellite MNS16A is associated with the risk of prostate cancer and/or lung 
cancer. 
Figure 6:  Hofer et al. 2011; Nucleotide sequence of wild-ty
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Based on a prostate cancer study population of 1774 Austrian participants, the role of 
MNS16A-single alleles, genotypes and SL-genotypes as potential biomarkers to distinguish 
between the aggressive and the indolent form of prostate cancer was assessed. A marker to 
estimate the aggressiveness of prostate cancer helps to adapt cancer treatment. In addition, 
MNS16A variants were investigated as potential biomarkers for lung cancer risk within a 
study population of 3134 Austrian participants. Finding a minimal invasive marker for lung 
cancer is an essential issue, particularly because early detection of lung cancer is fundamental 
for lung cancer therapy.  
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2. Material and Methods  
 
2.1. Material 
2.1.1. Study population 
2.1.1.1. Prostate cancer 
Blood samples of the prostate cancer cohort were collected in the general hospital, the 
Sozialmedizinisches Zentrum Süd (or Kaiser Franz-Josef hospital), and the 
Sozialmedizinisches Zentrum Ost. Together with the written informed consent, a short 
questionnaire on the smoking habits was obtained. 
The study population comprised 1137 newly diagnosed prostate cancer cases and 637 
hospital-based controls with BPH. Case subjects were classified according to the 
aggressiveness of their tumor in 505 patients with Gleason Score 2-6 and 490 patients with 
Gleason Score 7-10. For all patients, histological records were available. All controls 
underwent biopsy of the prostate and were therefore known to be free of prostate cancer.  
 
2.1.1.2. Lung cancer 
Blood samples of the lung cancer cohort were collected from the LHK Grimmenstein 
Hochegg and from the Sozialmedizinisches Zentrum Baumgartner Höhe. The study 
population comprised 665 lung cancer patients that can be further classified in 132 SCLC 
patients and 533 NSCLC patients. The control group comprised 2469 participants and 
consisted of 757 hospital-based controls including 120 orthopedics controls and 637 BPH 
controls and additional 1712 population-based controls.  
 
2.2.Methods 
2.2.1. DNA Isolation  
Isolation of genomic DNA from peripheral blood was performed with a spin-column based 
nucleic acid purification kit, namely QIAamp DNA blood midi kit (QIAGEN, Hilden 
Germany), according to manufacturer’s instructions.  
200µl QIAGEN Protease solution were provided in a 15ml tube, 1-2ml peripheral blood were 
added and mixed briefly. 2.4ml lysis Buffer AL were added followed by mixing for one 
minute, before the tubes were placed in a shaking water bath for 30min at 70°C. After the 
samples cooled down for a few minutes, 2ml 100% Ethanol were added to each sample and 
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mixed for one minute. Half of the lysate was transferred onto the midi spin column and 
centrifuged for 5min at 1850xg (Eppendorf Centrifuge 5810 R, Eppendorf Germany). The 
remaining half was also transferred onto the same midi spin column and centrifuged on equal 
terms. The membrane bound DNA was rinsed with 2ml wash Buffer AW1 and centrifuged for 
2min at 4000rpm. Afterwards 2ml wash Buffer AW2 were pipetted onto the spin column and 
tubes were centrifuged for 18min at 4000rpm. Purified DNA was eluted with 300µl elution 
Buffer AE. After 5min of incubation at room temperature, tubes were centrifuged for 7min at 
4000rpm.  
The concentration of genomic DNA was quantified by Nanodrop ND-1000 
Spectrophotometer (PEQLAB Biotechnologie GmbH, Erlangen Germany) as provided in 
manufacturer’s instructions. Purified DNA was stored at -80°C. Working dilutions of 10ng/µl 
were obtained by dilution with Aqua bidest. “Fresenius” (Fresenius Kabi, Austria) and stored 
at -20°C.   
 
2.2.2. Genotyping of MNS16A 
MNS16A genotypes were determined by PCR amplification followed by electrophoretical 
separation in 2.5% agarose gels and visualization of PCR products using UV light excitation. 
Standard PCR was done in 20µl reactions containing 40ng of genomic DNA and 16µl master 
mix set up in 0.2ml PCR SOFTTUBES (Biozym, Hessen Germany). 
Master mix consisted of  2µl Gene Amp 10xPCR Buffer II (Applied Biosystems, California 
US), 1.2µl 25mM MgCl2 Solution (Applied Biosystems, California US), 0.3 µl dNTP Mix, 
10mM each (Applied Biosystems, California, US), each 3.5µl 5µM forward (5`-AGG ATT 
CTG ATC TCT GAA GGG TG-3`) and reverse primer (5`-TCT  GCC  TGA GGA AGG 
ACG TAT G-3`) (VBC-BIOTECH Service, Vienna Austria), 0.06µl 5 U/µl AmpliTaq DNA 
Polymerase (Applied Biosystems, California US) and 5.44µl Aqua bidest. “Fresenius” 
(Fresenius Kabi, Austria).The whole procedure was carried out on ice. 
PCR amplification was performed on a 2720 Thermal Cycler (Applied Biosystem, California 
US) by the following thermal profile: initial denaturing step for 5min at 95°C followed by 35 
cycles of 95°C (30s), 65°C (30s), 72°C (30s) and a final extension step of 10min at 72°C.  
For visualization of PCR amplicons agarose gel electrophoresis coupled with UV detection of 
the Ethidium Bromid (EtBr) stained DNA molecules was accomplished. Hence, 50ml 2.5% 
agarose gels were set up after following formula: 1.25g agarose (Biozym LE Agarose 
[Biozym, Hessen Germany]) were disbanded in 50ml 1xTBE buffer (10.8g/L 
Tris(hydroxymethyl)-aminomethane [Merck, Darmstadt Germany], 5.5 g/L boracid acid [Alfa 
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Aesar, Karlsruhe Germany], 4ml/L 0.5M EDTA pH8 [Merck, Darmstadt Germany]) and 
mixed with 25ng EtBr (Amresco, Ohio US).  
Electrophoretical separation was carried out in Hoefer HE 33 Mini Horizontal Submarine 
Units (Pharmacia Biotech, Zurich Switzerland) at 130V for 50min. 20µl PCR product and 
additional 4µl 6x Loading Dye (Fermentas Int. Inc., Ontario Canada) were loaded. On each 
gel 0.2ng GeneRuler 50bp DNA Ladder (Fermentas Int. Inc., Ontario Canada) was loaded as 
length standard. Genotype patterns were made visible by UV light exposure of EtBr stained 
agarose gels with GelDoc detection system (Bio-Rad Laboratories, California US).   
2.2.3. Cloning of MNS16A PCR products 
Cloning of MNS16A PCR products was performed with TOPO TA Cloning Kit Dual 
Promoter, containing pCRII-TOPO plasmid (Figure 7) utilizing chemically competent TOP10 
bacterial cells for transformation and blue/white screening, without IPTG as an induction 
molecule, following manufacturer´s instructions (Invitrogen, California US).   
TOPO TA Cloning kit provides direct insertion of Taq polymerase amplified, sticky end 
products into plasmid vector. Taq polymerase is supplied with a nontemplate-dependent  
terminal transferase activity that adds a single deoxyadenosine to the 3´ends of the amplified 
sequence. The linearized plasmid pCRII-TOPO is equipped with compatible deoxythymedine 
overhangs. Furthermore, the supplied plasmid is activated by the covalently bound enzyme 
topoisomerase I. Topoisomerase I cleaves duplex DNA after the sequence 5`-CCCTT in one 
strand. The resulting energy is conserved in a covalent bond between the 3`phosphate of the 
cleaved strand and a tyrosyl residue of topoisomerase I. This bond can be attacked by a 
5`hydroxyl group, and consequently topoisomerase is released. For this reasons, insertion can 
happen directly, without any post PCR modifications nor the use of ligase. 
 
Cloning Reaction 
The cloning reaction was made of 0.5µl salt solution (1.2 M NaCl, 0.06M MgCl2), 0.5µl 
vector (10ng/µl plasmid DNA provided in 50% glycerol, 1mM EDTA, 1mM DTT, 0.1% 
Triton X-100, 100µg/ml BSA, 50mM Tris-HCL pH 7.4 and phenol red) and 2µl PCR product. 
After 20min of incubation at room temperature, the mixture was placed on ice. 
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Transformation 
Two vials of One Shot chemically competent E.coli, each with 200µl volume, were thawed on 
ice. In one vial 4µl of the prepared TOPO cloning mixture were added and mixed gently. To 
determine the transformation efficiency 4µl 10pg/µl pUC 19 DNA (Invitrogen, California 
US) were added to the second vial of chemically competent cells. The following 
transformation steps were performed equally for cloning and control reaction. After an 
incubation on ice (20min), a heat shock of 30sec at 42°C was applied by water bath, whereby 
cell membranes get temporary porous and plasmids are able to enter.   
Instantly, vials were placed on ice and 250ml room tempered SOC medium (6ml SOB 
medium, 60µl 1M MgCl2 [Merck, Darmstadt Germany] , 60µl 2M glucose [Sigma-Aldrich, Inc., 
Missouri US]) were added. SOB medium was made of 20g/L Tryptone (Roth, Karlsruhe 
Germany), 5g/L yeast extract (Sigma-Aldrich Inc., Missouri US), 0.5g/L NaCl (Merck, 
Figure 7: Invitrogen, Cloning site of PCRII- TOPO vector 
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Darmstadt Germany), 10ml 250mM KCL (Merck, Darmstadt Germany) and was finally 
adjusted to pH 7 with NaOH (Merck, Darmstadt Germany). Cell suspensions were then 
incubated at 37°C and 200rpm for 1 hour to induce the expression of antibiotic resistances. 
50µl of each transformation suspension were plated on pre-warmed selective LB agar plates 
(20g/L LB, 15g/L agar [Sigma-Aldrich Inc., Missouri US] and 100µg/ml ampicillin 
[AppliChem, Darmstadt Germany]), previously plated with 40µl X-gal (AppliChem, 
Darmstadt Germany). The plates were incubated over night at 37°C. 
Next day, white colonies were picked and solitary transferred to 14ml tubes, containing 5ml 
ampicillin-dosed LB-medium. For picking, sterile single-use loops (Nunc, Wiesbaden 
Germany) were utilized.  
Cell suspensions were incubated over night at 37°C and 230rpm.  
To assure, that the right PCR product inserted into plasmid vector while TOPO cloning 
reaction, a PCR was accomplished. Therefore, 4µl of overnight culture were diluted with 95µl 
“Fresenius” aqua bidest. (Fresenius kabi, Austria) and heated for 15min at 95°C. This way, 
cell membrane and wall disrupt and release the plasmid. 1µl plasmid DNA suspension was 
then used as template for MNS16A-specific PCR, followed by an electrophoretical separation 
in 2.5% agarose gels. Expected PCR product lengths confirm a successful cloning.  
Positive overnight cultures underwent the procedure of plasmid DNA isolation utilizing 
Wizard Plus SV Minipreps DNA Purification System (Promega, California US). The 
production of a cleared lysate was carried out following the provided protocol, comprising 
harvest and lysis of bacterial cells.  
Plasmid DNA was then precipitated and purified according to the provided centrifugation 
protocol, and finally eluted in 30µl nuclease free water. For sequencing, 10µl at a 
concentration of 80ng/µl was sent to Microsynth (Balgach, Switzerland).   
 
2.3. Statistical analysis  
Statistical analysis was performed in the R programming environment and carried out by Mr. 
Andreas Baierl. Control groups were tested for Hardy-Weinberg Equilibrium (HWE) using a 
Chi2 -test, which is important as a quality control. By multiple logistic regression, odds ratios 
and 95% confidence intervals were estimated for the genotype, the single VNTRs and the SL 
classification. Covariants age and smoking were used in all models as confounders; 
additionally, gender was used in the lung cancer population.  
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3. Results 
3.1. Studypopulation 
3.1.1. Prostate Cancer Cohort 
The prostate cancer study population comprised 1787 participants, composed of 1137 newly 
diagnosed prostate cancer cases and 650 controls with BPH. The age distribution was 
significantly different between cases and controls, with a mean age of 63.8 years for the cases 
and 67.4 years for the BPH controls. Therefore all statistical models were adjusted for age. 
Smoking habits did not significantly differ between carcinoma patients and control subjects. 
58.1% of all cases were classified as former or current smokers, in the control group it was 
slightly more. For 87 cases and 31 controls no data regarding smoking habits were available 
(Table 1). 
 
 
 
 
 PC patients 
Gleason Score 
<7 
Gleason Score 
>=7  BPH Controls 
    
 N (%) N (%) N (%) N (%) 
Age (years)     
<50 55 (4.8) 32 (6.3) 21 (4.3) 18 (2.8) 
<60 308 (27.1) 136 (26.9) 127 (25.9) 133 (20.5) 
<70 563 (49.5) 259 (51.3) 244 (49.8) 270 (41.5) 
<80 190 (16.7) 73 (14.5) 90 (18.4) 181 (27.8) 
>80 21 (1.8) 5 (1.0) 8 (1.6) 48 (7.4) 
Total 1137 (100) 505 (100) 490 (100) 650 (100) 
Mean Age (SD a) 63.8 ( 7.7) 63.4 (7.6) 63.9 (7.5) 67.4 (8.9) 
Smoking     
never 435 (41.4) 188 (40.7) 189 (41.7) 238 (38.4) 
former 465 (44.3) 203 (43.9) 199 (43.9) 291 (47.0) 
current 150 (14.3) 71 (15.4) 65 (14.3) 90 (14.5) 
Smoking rate b  615 (58.6) 274 (59.3) 264 (58.2) 381 (61.5) 
Total 1050 (100) 462 (100) 453 (100) 619 (100) 
 
 
 
 
3.1.2. Lung Cancer Cohort 
Demographic factors and smoking history were evaluated in the lung cancer study population 
consisting of 3167 participants. The lung cancer patients (n= 619) were classified according to 
their histological subtype in a SCLC (n=125) and a NSCLC (n=476) subgroup. The entire 
control group encompassing 2548 subjects consisted of 118 orthopedics controls, 650 BPH 
Table 1. Age distribution and smoking status of prostate cancer study population 
a Standard deviation;  b Former and current smokers 
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controls and 1780 population-based controls. Men were significantly overrepresented in the 
case group, composing 69.1% of all cases. Due to the BPH control subgroup, men were also 
more prevalent in the total control population. The mean ages of cases and controls were 
significantly different, with a mean age of 63.4 years for the cases, 62.0 years for the 
orthopedics controls, 67.4 years for the BPH controls and 61.3 years for the population-based 
controls. The average mean age was slightly lower in the control group, compared to the case 
group. Smokers were significantly overrepresented in the case group, with 47.1% former and 
42.4% current smokers, while it was 32.4% former and 14.9% current smokers in the overall 
control population. For 165 participants no information on their smoking status was available. 
All lung models were adjusted for gender, age and smoking (Table 2). The MNS16A 
genotype distribution of all control groups were found to be within the HWE.  
 
 
 
  
Lung 
cancer 
patients SCLC NSCLC 
Ortho. 
Controls 
BPH 
Controls 
Pop.-based 
Controls 
Total 
Controls 
        
  N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Sex        
Male 428 (69.1) 86 (68.8) 331 (69.5) 44 (37.3) 650 (100) 829 (46.6) 1523 (59.8) 
Female 191 (30.9) 39 (31.2) 145 (30.5) 74 (62.7) 0 951 (53.4) 1025 (40.2) 
Total 619 (100) 125 (100) 476 (100) 118 (100) 650 (100) 1780 (100) 2548 (100) 
Age (years)        
<50 68 (11.0) 11 (8.8) 55 (11.6) 21 (17.8) 18 (2.8) 339 (19.0) 378 (14.8) 
<60 188 (30.4) 40 (32.0) 142 (29.8) 29 (24.6) 133 (20.5) 428 (24.0) 590 (23.2) 
<70 196 (31.7) 43 (34.4) 149 (31.3) 36 (30.5) 270 (41.5) 554 (31.1) 860 (33.8) 
<80 141 (22.8) 27 (21.6) 108 (22.7) 25 (21.2) 181 (27.8) 428 (24.0) 634 (24.9) 
>80 26 (4.2) 4 (3.2) 22 (4.6) 7 (5.9) 48 (7.4) 31 (1.7) 86 (3.4) 
Total 619 (100) 125 (100) 476 (100) 118 (100) 650 (100) 1780 (100) 2548 (100) 
Mean Age (SD a) 63.4 (10.1) 63.2 (9.9) 63.4 (10.3) 62.0 (12.9) 67.4 (8.9) 61.3 (11.2) 62.9 (11.1) 
Smoking        
Never 63 (10.6) 7 (5.9) 52 (11.3) 46 (39.7) 238 (38.4) 1017 (58.7) 1301 (52.7) 
Former 281 (47.1) 56 (47.5) 216 (46.9) 41 (35.3) 291 (47.0) 467 (26.9) 799 (32.4) 
Current 253 (42.4) 55 (46.6) 193 (41.9) 29 (25.0) 90 (14.5) 249 (14.4) 368 (14.9) 
Smoking rate b 534 (89.5) 111 (94.1) 409 (88.8) 70 (60.3) 381 (61.5) 716 (41.3) 1167 (47.3) 
Total 597 (100) 118 (100) 461 (100) 116 (100) 619 (100) 1733 (100) 2468 (100) 
 
 
Table 2. Sex/Age distribution and smoking status of lung cancer study population 
a Standard deviation;  b Former and current smokers 
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3.2. MNS16A genotyping 
MNS16A genotyping was successful in 98.1% of prostate samples and in 98.6% of lung 
samples. Six different VNTRs of MNS16A were identified (VNTR-364,-333,-302,-274,-243,-
212), including the newly found variant VNTR-212. VNTRs are termed according to their 
PCR fragment size and are illustrated in Figure 8. The shortest variant, VNTR-212, was 
discovered for the first time in this study. MNS16A alleles appeared in 12 different genotype 
patterns, which are summarized in Table 3. Two genotypes, namely the homozygote 274/274 
genotype and the genotype 212/302, containing the novel allele, were also found for the first 
time. Alleles can be classified in short (S) (VNTR-212,-243,-274) and long (L) (VNTR-302,-
333,-364) variants, resulting in SL-genotypes (table 3). The rare genotypes 212/302 and 
274/274 were found only once and were therefore excluded from statistical models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The identity of the newly found variant was verified by cloning and sequencing and the 
nucleotide sequence is illustrated in Figure 9. The five previously known VNTRs are shown 
in Figure 10. VNTR-212 is the shortest VNTR that has been reported so far and contains only 
two of the characteristic tandem repeats. It is 31 base pairs shorter than the VNTR-243 and 
contains only one CAT trinucleotide insert, thereby carrying also the smallest number in 
transcription factor binding sites.  
 
 
Genotype SL-classification 
 
302/302 
 
LL 
243/243 SS 
243/302 SL 
302/333 LL 
243/274 SS 
274/302 SL 
243/333 SL 
333/333 LL 
302/364 LL 
274/333 SL 
274/274 SS 
212/302 SL 
Figure 8. Six different VNTRs of MNS16A 
Table 3. Genotype patterns 
 VNTR-  212-243-274-302-333-364   
400bp 
300bp 
250bp 
200bp 
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3.2.1. Prostate cancer  
3.2.1.1. Overall study population 
By multiple logistic regression analysis, no significant effects were observed in the overall 
prostate cancer population. The genotype distribution of cases and controls are illustrated in 
Figure 11, genotype, allele and SL-genotype distribution, containing odds ratio (OR), 95% 
confidence interval and p-value, are summarized in Table 4.   
 
 
Figure 9. Base sequence of VNTR-212 
Figure 10. Hofer et al. 2011; Base sequence 
VNTR-243,-274,-302,-333,-364. 
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BPH-
Controls PC patients 
     
Genotype N (%) N (%) OR a (95% CI b) P-value 
302/302 287 (44.2) 474 (41.7) 1.00  
243/243 58 (8.9) 124 (10.9) 1.27 (0-89-1.81) 0.180 
243/302 258 (39.7) 472 (41.5) 1.13 (0.91-1.41) 0.261 
302/333 21 (3.2) 27 (2.4) 0.75 (0.41-1.36) 0.341 
243/274 7 (1.1) 13 (1.1) 1.03 (0.40-2.66) 0.958 
274/302 18 (2.8) 18 (1.6) 0.67 (0.33-1.34) 0.252 
243/333 1 (0.2) 9 (0.8) 4.43 (0.56-35.26) 0.160 
Total 650 (100) 1137 (100)   
Alleles         
302 871 (67.0) 1465 (64.4) 1.00  
243 382 (29.4) 742 (32.6) 1.15 (0.99-1.34) 0.068 
274 25 (1.9) 31 (1.4) 0.76 (0.44-1.31) 0.321 
333 22 (1.7) 36 (1.6) 0.90 (0.52-1.56) 0.719 
SL-
Genotype         
LL 308 (47.4) 501 (44.1) 1.00  
SL 277 (42.6) 499 (43.9) 1.14 (0.92-1.40) 0.229 
SS 65 (10.0) 137 (12.0) 1.27 (0.91-1.77) 0.165 
SL+SS 342 (52.6) 636 (55.9) 1.16 (0.95-1.42) 0.140 
 
 
 
Figure 11. Genotype distribution of the prostate cancer study population 
 
Table 4. Genotype distribution of the prostate cancer study population 
 
a Odds ratio; b 95% confidence interval 
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3.2.1.2. Subpopulation ≥ 70 years 
In a subgroup analysis of men aged 70 and older the genotype 274/302 was associated with a 
significantly reduced risk of prostate cancer, when compared to the wild-type genotype 
(OR=0.09) Also, regarding the single alleles model this effect for VNTR-274 remained 
significant with an OR of 0.23. All results are summarized in Table 5, significant associations 
are given in bold.  
 
 
 
 
 
 
BPH-
Controls PC patients ≥ 70 
     
Genotype N (%) N (%) OR a (95% CI b) P-value 
302/302 94 (41.0) 91 (43.1) 1.00  
243/243 22 (9.6) 21 (10.0) 0.85 (0.42-1.71) 0.653 
243/302 92 (40.2) 92 (43.6) 1.10 (0.72-1.70) 0.658 
302/333 8 (3.5) 4 (1.9) 0.48 (0.14-1.70) 0.257 
243/274 2 (0.9) 2 (0.9) 0.99 (0.12-8.45) 0.998 
274/302 11 (4.8) 1 (0.5) 0.09 (0.01-0.72) 0.023 
Total 229 (100) 211 (100)   
Alleles        
302 299 (65.3) 279 (66.1) 1.00  
243 138 (30.1) 136 (32.2) 1.04 (0.76-1.40) 0.821 
274 13 (2.8) 3 (0.7) 0.23 (0.06-0.83) 0.026 
333 8 (1.7) 4 (0.9) 0.49 (0.14-1.70) 0.262 
SL-Genotype        
LL 102 (44.5) 95 (45.0) 1.00  
SL 103 (45.0) 93 (44.1) 1.03 (0.68-1.56) 0.895 
SS 24 (10.5) 23 (10.9) 0.90  (0.46-1.77) 0.768 
SL+SS 127 (55.5) 116 (55.0) 1.00 (0.67-1.49) 0.990 
 
 
 
 
 
 
 
 
 
 
Table  5. Genotype distribution of the prostate cancer study population ≥ 70  
 
a Odds ratio; b 95% confidence interval 
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3.2.2. Lung cancer 
3.2.2.1. Overall study population 
In our overall lung cancer population, no evidence of a significant association of MNS16A 
genotypes with risk of lung cancer was identified. By analysing the genotype distribution of 
all control groups compared to the case group no significant effects could be observed, as 
summarized in Table 6 and visualized in Figure12. Same results were obtained by 
investigation of associations between the control subgroups and the total control group with 
the NSCLC subpopulation (Table 7).  
 
 
 
 
 
 
Figure 12. Genotype distribution of the lung cancer study population 
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Table 6. Genotype distribution of lung cancer study population 
 
 
           
  
  
Lung cancer 
patients Population based  Controls Hospital based Controls  Total Controls 
               
Genotype N (%) N (%) OR a (95% CI b) P-value N (%) OR a (95% CI b) P-value N (%) OR a (95% CI b) P-value 
302/302 270 (45.2) 740 (42.7) 1   317 (43.1) 1  1057 (42.8) 1  
243/243 56 (9.4) 186 (10.7) 0.83 (0.57-1.21) 0.335 68 (9.3) 0.88 (0.57-1.36) 0.57 254 (10.3) 0.86 (0.61-1.21) 0.379 
243/302 230 (38.5) 701 (40.5) 0.92 (0.73-1.16) 0.489 298 (40.5) 0.92 (0.70-1.20) 0.543 999 (40.5) 0.94 (0.76-1.16) 0.567 
302/333 15 (2.5) 35 (2.0) 1.16 (0.56-2.41) 0.685 23 (3.1) 0.76 (0.36-1.61) 0.48 58 (2.4) 0.88 (0.47-1.66) 0.704 
243/274 4 (0.7) 14 (0.8) 0.96 (0.25-3.70) 0.957 7 (1.0) 0.50 (0.13-1.91) 0.309 21 (0.9) 0.71 (0.22-2.31) 0.572 
274/302 18 (3.0) 41 (2.4) 1.48 (0.75-2.90) 0.257 21 (2.9) 0.95 (0.44-2.03) 0.894 62 (2.5) 1.18 (0.65-2.16) 0.582 
243/333 4 (0.7) 16 (0.9) 0.74 (0.22-2.47) 0.624 1 (0.1) 6.54 (0.55-77.40) 0.136 17 (0.7) 1.09 (0.34-3.56) 0.884 
Total 597 (100) 1733 (100)    735 (100)   2468 (100)   
Alleles                     
302 803 (67.3) 2257 (65.1) 1   976 (66.4) 1  3233 (65.5) 1  
243 350 (29.3) 1103 (31.8) 0.90 (0.76-1.06) 0.217 442 (30.1) 0.94 (0.77-1.13) 0.506 1545 (31.3) 0.93 (0.80-1.08) 0.318 
274 22 (1.8) 55 (1.6) 1.38 (0.76-2.49) 0.294 28 (1.9) 0.84 (0.44-1.61) 0.6 83 (1.7) 1.08 (0.64-1.83) 0.778 
333 19 (1.6) 51 (1.5) 1.04 (0.56-1.92) 0.896 24 (1.6) 0.98 (0.50-1.93) 0.954 75 (1.5) 0.94 (0.54-1.63) 0.827 
SL-Genotyp                    
LL 285 (47.7) 775 (44.7) 1   340 (46.3) 1  1115 (45.2) 1  
SL  252 (42.2) 758 (43.7) 0.94 (0.75-1.17) 0.566 320 (43.5) 0.95 (0.73-1.23) 0.704 1078 (43.7) 0.96 (0.78-1.18) 0.712 
SS 60 (10.1) 200 (11.5) 0.83 (0.58-1.20) 0.324 75 (10.2) 0.85 (0.56-1.30) 0.457 275 (11.1) 0.85 (0.61-1.19) 0.344 
SL+SS 312 (52.3) 958 (55.3) 0.91 (0.74-1.13) 0.412 395 (53.7) 0.93 (0.73-1.19) 0.566 1353 (54.8) 0.94 (0.77-1.14) 0.524 
a Odds ratio; b 95% confidence interval 
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Table 7. Genotype distribution of the NSCLC study population 
 
 
 
          
  
NSCLC 
patients Population based controls Hospital based controls Total Controls 
                
Genotype N (%) N (%) OR a  (95% CI b) P-value N(%) OR a  (95% CI b) P-value N(%) OR a  (95% CI b) P-value 
302/302 216 (46.9) 740 (42.7) 1  317 (43.1) 1   1057 (42.8) 1  
243/243 43 (9.3) 186 (10.7) 0.78 (0.52-1.17) 0.236 68 (9.3) 0.83 (0.52-1.33) 0.45 254 (10.3) 0.81 ( 0.56-1.19) 0.279 
243/302 169 (36.7) 701 (40.5) 0.86 (0.66-1.11) 0.236 298 (40.5) 0.87 (0.66-1.16) 0.36 999 (40.5) 0.88 (0.69-1.11) 0.268 
302/333 12 (2.6) 35 (2.0) 1.24 (0.57-2.69) 0.584 23 (3.1) 0.74 (0.33-1.64) 0.457 58 (2.4) 0.89 (0.45-1.76) 0.739 
243/274 2 (0.4) 14 (0.8) 0.73 (0.14-3.84) 0.712 7 (1.0) 0.30 (0.06-1.64) 0.166 21 (0.9) 0.47 (0.10-2.17) 0.332 
274/302 16 (3.5) 41 (2.4) 1.70 (0.85-3.40) 0.134 21 (2.9) 1.01 (0.46-2.20) 0.977 62 (2.5) 1.33 (0.72-2.49) 0.365 
243/333 3 (0.7) 16 (0.9) 0.68 (0.18-2.57) 0.565 1 (0.1) 5.71 (0.39-82.73) 0.202 17 (0.7) 0.99 (0.27-3.69) 0.989 
Total 461 (100) 1733 (100)   735 (100)    2468 (100)   
Alleles                     
302 629 (68.2) 2257 (65.1) 1  976 (66.4) 1   3233 (65.5) 1  
243 260 (28.2) 1103 (31.8) 0.85 (0.71-1.02) 0.083 442 (30.1) 0.90 (0.73-1.10) 0.297 1545 (31.3) 0.88 (0.74-1.04) 0.13 
274 18 (2.0) 55 (1.6) 1.52 (0.82-2.85) 0.186 28 (1.9) 0.84 (0.42-1.67) 0.616 83 (1.7) 1.15 (0.65-2.02) 0.628 
333 15 (1.6) 51 (1.5) 1.09 (0.56-2.09) 0.806 24 (1.6) 0.93 (0.45-1.93) 0.847 75 (1.5) 0.94 (0.52-1.71) 0.842 
SL-Genotype   3466 (100)                 
LL 228 (49.5) 775 (44.7) 1  340 (46.3) 1   1115 (45.2) 1  
SL  188 (40.8) 758 (43.7) 0.88 (0.69-1.13) 0.319 320 (43.5) 0.91 (0.69-1.20) 0.511 1078 (43.7) 0.91 (0.73-1.14) 0.409 
SS 45 (9.8) 200 (11.5) 0.77 (0.52-1.15) 0.198 75 (10.2) 0.79 (0.50-1.24) 0.309 275 (11.1) 0.79 (0.55-1.14) 0.213 
SL+SS 233 (50.5) 958 (55.3) 0.86 (0.68-1.08) 0.198 395 (53.7) 0.89 (0.68-1.15) 0.365 1353 (54.8) 0.88 (0.71-1.09) 0.258 
a Odds ratio; b 95% confidence interval 
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3.2.2.2. Subpopulation ≥ 70 years   
For the age group of 70 or above, the genotype 243/302 was found to be associated with a 
significant decreased lung cancer risk when cases were compared to the hospital based control 
population. This reduced risk is reflected by an OR of 0.61 as illustrated in Table 8. If cases 
were limited to NSCLC, the genotype 243/302, which contains the short VNTR-243, was 
found to be associated with a decreased risk of NSCLC, with an OR of 0.53 for the hospital 
based controls and an OR of 0.62 for the total control group. A significant protective 
influence, regarding the single VNTR-243, was also observed in each control group, with 
ORs ranging from 0.63 to 0.66. This effect remained significant in the SL group, that contains 
the short VNTR-243 (OR=0.59;0.65).The SL+SS group was also found to be significantly 
associated with an reduced NSCLC risk in all control populations, with ORs ranging from 
0.58 to 0.64. Moreover, the genotype 302/333 conferred a significant decrease in NSCLC risk 
if cases were compared to the hospital based controls (OR= 0.15; Table 9)
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Table 8. Genotype distribution of lung cancer study population ≥ 70   
 
 
 
  
Lung cancer 
patients Population based Controls Hospital based Controls Total Controls 
              
Genotype N (%) N (%) OR a (95% CI b) P-value N (%) OR a (95% CI b) P-value N (%) OR a (95% CI b) P-value 
302/302 79 (49.4) 186 (42.2) 1   97 (39.1) 1  283 (41.1) 1  
243/243 13 (8.1) 49 (11.1) 0.63 (0.30-1.35) 0.236 22 (8.9) 0.67 (0.30-1.54) 0.349 71 (10.3) 0.65 (0.33-1.30) 0.224 
243/302 58 (36.3) 183 (41.5) 0.80 (0.50-1.26) 0.326 107 (43.1) 0.61 (0.38-0.99) 0.045 290 (42.1) 0.74 (0.49-1.10) 0.135 
302/333 4 (2.5) 6 (1.4) 1.00 (0.23-4.25) 0.998 8 (3.2) 0.38 (0.09-1.58) 0.185 14 (2.0) 0.67 (0.20-2.25) 0.515 
243/274 1 (0.6) 3 (0.7) 0.83 (0.04-17.5) 0.905 2 (0.8) 0.38 (0.03-4.58) 0.443 5 (0.7) 0.44 (0.04-4.61) 0.491 
274/302 5 (3.1) 10 (2.3) 2.05 (0.54-7.70) 0.29 12 (4.8) 0.66 (0.20-2.15) 0.487 22 (3.2) 0.92 (0.32-2.71) 0.886 
243/333 0 (0.0) 4 (0.9) x x 0 (0.0) x x 4 (0.6) X x 
Total 160 (100) 441 (100)    248 (100)   689 (100)   
Alleles                     
302 225 (70.3) 571 (64.7) 1   321 (64.7) 1  892 (64.7) 1  
243 85 (26.6) 288 (32.7) 0.76 (0.55-1.06) 0.107 153 (30.8) 0.74 (0.53-1.06) 0.097 441 (32.0) 0.77 (0.57-1.03) 0.079 
274 6 (1.9) 13 (1.5) 1.85 (0.56-6.10) 0.315 14 (2.8) 0.71 (0.25-2.02) 0.519 27 (2.0) 0.88 (0.34-2.33) 0.804 
333 4 (1.3) 10 (1.1) 0.67 (0.19-2.43) 0.542 8 (1.6) 0.46 (0.12-1.83) 0.27 18 (1.3) 0.61 (0.19-1.94) 0.403 
SL-Genotype                    
LL 83 (51.9) 192 (43.5) 1   105 (42.3) 1   297 (43.1) 1  
SL  63 (39.4) 197 (44.7) 0.81 (0.52-1.27) 0.363 119 (48.0) 0.65 (0.41-1.04) 0.07 316 (45.9) 0.75 (0.51-1.11) 0.154 
SS 14 (8.8) 52 (11.8) 0.64 (0.30-1.34) 0.234 24 (9.7) 0.68 (0.31-1.49) 0.331 76 (11.0) 0.65 (0.33-1.26) 0.201 
SL+SS 77 (48.1) 249 (56.5) 0.78 (0.51-1.18) 0.237 143 (57.7) 0.66 (0.42-1.02) 0.06 392 (56.9) 0.73 (0.51-1.06) 0.098 
a Odds ratio; b 95% confidence interval 
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Table 9. Genotype distribution of the NSCLC study population ≥ 70 
    
    
  
NSCLC 
patients Population based controls Hospital based controls Total Controls 
                
Genotype N (%) N (%) OR a  (95% CI b) P-value N (%) OR a  (95% CI b) P-value N(%) OR a  (95% CI b) P-value 
302/302 68 (54.4) 186 (42.2) 1  97 (39.1) 1   283 (41.1) 1  
243/243 9 (7.2) 49 (11.1) 0.45 (0.19-1.06) 0.068 22 (8.9) 0.54 (0.21-1.36) 0.189 71 (10.3) 0.50 (0.23-1.09) 0.08 
243/302 42 (33.6) 183 (41.5) 0.66 (0.40-1.08) 0.1 107 (43.1) 0.53 (0.31-0.89) 0.017 290 (42.1) 0.62 (0.40-0.97) 0.035 
302/333 2 (1.6) 6 (1.4) 0.58 (0.09-3.54) 0.554 8 (3.2) 0.15 (0.02-0.97) 0.046 14 (2.0) 0.36 (0.07-1.77) 0.211 
243/274 0 (0.0) 3 (0.7) x x 2 (0.8) x x 5 (0.7) x x 
274/302 4 (3.2) 10 (2.3) 1.87 (0.44-7.86) 0.394 12 (4.8) 0.60 (0.17-2.18) 0.44 22 (3.2) 0.84 (0.26-2.71) 0.768 
243/333 0 (0.0) 4 (0.9) x x 0 (0.0) x x 4 (0.6) x x 
Total 125 (100) 441 (100)   248 (100)    689 (100)   
Alleles                     
302 184 (73.6) 571 (64.7) 1  321 (64.7) 1   892 (64.7) 1  
243 60 (24.0) 288 (32.7) 0.63 (0.44-0.91) 0.014 153 (30.8) 0.65 (0.45-0.96) 0.03 441 (32.0) 0.66 (0.47-0.91) 0.012 
274 4 (1.6) 13 (1.5) 1.69 (0.44-6.45) 0.446 14 (2.8) 0.59 (0.18-1.98) 0.392 27 (2.0) 0.74 (0.24-2.28) 0.597 
333 2 (0.8) 10 (1.1) 0.41 (0.08-2.14) 0.292 8 (1.6) 0.20 (0.03-1.19) 0.076 18 (1.3) 0.36 (0.08-1.65) 0.188 
SL-Genotype                     
LL 70 (56.0) 192 (43.5) 1  105 (42.3) 1   297 (43.1) 1  
SL  46 (36.8) 197 (44.7) 0.69 (0.43-1.12) 0.131 119 (48.0) 0.59 (0.36-0.97) 0.037 316 (45.9) 0.65 (0.43-1.00) 0.052 
SS 9 (7.2) 52 (11.8) 0.45 (0.19-1.05) 0.064 24 (9.7) 0.52 (0.21-1.29) 0.157 76 (11.0) 0.48 (0.22-1.04) 0.062 
SL+SS 55 (44.0) 249 (56.5) 0.64 (0.40-1.00) 0.052 143 (57.7) 0.58 (0.36-0.93) 0.023 392 (56.9) 0.62 (0.41-0.93) 0.02 
a Odds ratio; b 95% confidence interval 
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3.2.2.3. Subpopulation ≤ 55 years 
In the stratified analysis for the age group ≤ 55 years, several associations were identified and 
the genotype, allele and SL-genotype distribution for the lung cancer cases and the population 
based, hospital based and total control group are summarized in Table 9. The genotype 
243/302 was found to be significantly associated with an increase in lung cancer risk when 
cases were compared to the hospital based controls. This elevated risk is illustrated by an OR 
of 2.58. The genotype 243/302 contains the short VNTR-243 that in turn is also associated 
with a 1.75fold increase in lung cancer risk within the same study population. The genotype 
containing the other short VNTR, genotype 274/302 was also found to be associated with an 
elevated lung cancer risk, reflected by an OR of 3.73, if the total control group is used, and an 
OR of 3.6, if controls are population based. Again these effects remained significant in the 
SL-classification system with ORs of 2.66, 2.46 and 1.57 for the SL and SS+SL genotypes, 
with either the control group containing hospital based controls or the total control group 
(Table 10).  
Furthermore, the genotype 243/302 was found to be associated with a significant increase in 
NSCLC risk in a study population aged 55 or younger, if controls were hospital based (OR= 
2.75). The enclosed VNTR-243 is also associated with a 1.75fold increase in NSCLC risk 
within the same study population. Genotype 274/302 is associated with a substantially 
elevated NSCLC risk, when either population based controls (OR= 4.54) or the total control 
group were considered (OR= 4.76). The SL-genotype, t includes the 243/302 genotype and 
the 274/302 genotype, was also associated with a raised risk of NSCLC, illustrated by an OR 
of 2.85 for the hospital based controls and 1.67 for the total controls. Moreover, the SL+SS 
group is associated with a 2.56fold increase in NSCLC risk, using the hospital based controls 
(Table 11). 
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Table 10. Genotype distribution of the lung cancer study population ≤ 55  
 
 
 
  
Lung cancer 
patients Population based Controls Hospital based Controls Total Controls 
              
Genotype N (%) N (%) OR a  (95% CI b) P-value N (%) OR a  (95% CI b) P-value N (%) OR a  (95% CI b) P-value 
302/302 51 (38.1) 239 (43.1) 1   49 (55.7) 1  288 (44.8) 1  
243/243 12 (9.0) 72 (13.0) 0.70 (0.33-1.48) 0.349 8 (9.1) 2.15 (0.68-6.82) 0.193 80 (12.4) 0.87 (0.42-1.79) 0.703 
243/302 57 (42.5) 205 (36.9) 1.26 (0.79-2.02) 0.338 28 (31.8) 2.58 (1.29-5.14) 0.007 233 (36.2) 1.49 (0.95-2.35) 0.083 
302/333 4 (3.0) 16 (2.9) 1.39 (0.40-4.89) 0.606 1 (1.1) 2.94 (0.31-27.81) 0.347 17 (2.6) 1.58 (0.47-5.38) 0.463 
243/274 1 (0.7) 7 (1.3) 0.67 (0.06-7.25) 0.744 1 (1.1) 0.68 (0.04-11.45) 0.786 8 (1.2) 0.74 (0.08-7.03) 0.792 
274/302 7 (5.2) 11 (2.0) 3.60 (1.08-12.06) 0.038 1 (1.1) 5.58 (0.61-51.40) 0.129 12 (1.9) 3.73 (1.19-11.69) 0.024 
243/333 2 (1.5) 5 (0.9) 1.85 (0.32-10.67) 0.492 0 (0.0) x x 5 (0.8) 2.38 (0.42-13.58) 0.328 
Total 134 (100) 555 (100)    88 (100)   643 (100)   
Alleles                     
302 170 (63.4) 710 (64.0) 1   128 (72.7) 1  838 (65.2) 1  
243 84 (31.3) 361 (32.5) 0.92 (0.67-1.27) 0.604 45 (25.6) 1.75 (1.07-2.86) 0.025 406 (31.6) 1.05 (0.77-1.43) 0.759 
274 8 (3.0) 18 (1.6) 2.17 (0.79-6.01) 0.134 2 (1.1) 2.12 (0.43-10.59) 0.358 20 (1.6) 2.12 (0.82-5.52) 0.123 
333 6 (2.2) 21 (1.9) 1.35 (0.49-3.70) 0.556 1 (0.6) 3.59 (0.42-30.56) 0.243 22 (1.7) 1.51 (0.56-4.05) 0.414 
SL-Genotype                    
LL 55 (41.0) 225 (42.9) 1   50 (56.8) 1   305 (47.4) 1  
SL  66 (49.3) 221 (42.1) 1.34 (0.86-2.10) 0.201 29 (33.0) 2.66 (1.36-5.20) 0.004 250 (38.9) 1.57 (1.02-2.41) 0.041 
SS 13 (9.7) 79 (15.0) 0.68 (0.33-1.40) 0.298 9 (10.2) 1.79 (0.61-5.25) 0.292 88 (13.7) 0.83 (0.42-1.67) 0.607 
SL+SS 79 (59.0) 300 (57.1) 1.16 (0.76-1.78) 0.491 38 (43.2) 2.46 (1.31-4.60) 0.005 338 (52.6) 1.37 (0.91-2.07) 0.132 
           
a Odds ratio; b 95% confidence interval 
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Table 11. Genotype distribution of the NSCLC study population ≤ 55  
 
    
     
  
NSCLC 
patients Population based Controls Hospital based Controls All Controls 
               
Genotype N (%) N (%) OR a (95% CI b) P-value N (%) OR a (95% CI b) P-value N (%) OR a (95% CI b) P-value 
302/302 39 (35.8) 239 (43.1) 1  49 (55.7) 1   288 (44.8) 1  
243/243 10 (9.2) 72 (13.0) 0.74 (0.33-1.64) 0.454 8 (9.1) 2.11 (0.65-6.91) 0.216 80 (12.4) 0.92 (0.42-2.01) 0.837 
243/302 47 (43.1) 205 (36.9) 1.32 (0.80-2.20) 0.281 28 (31.8) 2.75 (1.34-5.63) 0.006 233 (36.2) 1.58 (0.97-2.59) 0.067 
302/333 4 (3.7) 16 (2.9) 1.76 (0.50-6.22) 0.377 1 (1.1) 3.84 (0.40-36.56) 0.242 17 (2.6) 2.02 (0.59-6.91) 0.261 
243/274 0 (0.0) 7 (1.3) x x 1 (1.1) x x 8 (1.2) X x 
274/302 7 (6.4) 11 (2.0) 4.54 (1.36-15.19) 0.014 1 (1.1) 7.07 (0.77-65.17) 0.084 12 (1.9) 4.76 (1.52-14.95) 0.008 
243/333 2 (1.8) 5 (0.9) 2.35 (0.41-13.61) 0.34 0 (0.0) x x 5 (0.8) 3.05 (0.53-17-42) 0.21 
Total 109 (100) 555 (100)   88 (100)    643 (100)   
Alleles                     
302 136 (62.4) 710 (64.0) 1  128 (72.7) 1   838 (65.2) 1  
243 69 (31.7) 361 (32.5) 0.93 (0.66-1.31) 0.668 45 (25.6) 1.75 (1.06-2.90) 0.03 406 (31.6) 1.07 (0.76-1.49) 0.712 
274 7 (3.2) 18 (1.6) 2.46 (0.87-7.00) 0.09 2 (1.1) 2.30 (0.45-11.82) 0.318 20 (1.6) 2.38 (0.89-6.41) 0.085 
333 6 (2.8) 21 (1.9) 1.66 (0.61-4.52) 0.326 1 (0.6) 4.49 (0.53-38.33) 0.17 22 (1.7) 1.85 (0.69-4.97) 0.22 
SL-Genotype                     
LL 43 (39.4) 225 (42.9) 1  50 (56.8) 1   305 (47.4) 1  
SL  56 (51.4) 221 (42.1) 1.42 (0.88-2.30) 0.152 29 (33.0) 2.85 (1.43-5.69) 0.003 250 (38.9) 1.67 (1.05-2.66) 0.03 
SS 10 (9.2) 79 (15.0) 0.66 (0.30-1.46) 0.305 9 (10.2) 1.63 (0.53-5.04) 0.397 88 (13.7) 0.81 (0.38-1.75) 0.591 
SL+SS 66 (60.6) 300 (57.1) 1.21 (0.77-1.92) 0.406 38 (43.2) 2.56 (1.34-4.91) 0.005 338 (52.6) 1.44 (0.93-2.25) 0.106 
 
 
 
a Odds ratio; b 95% confidence interval 
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3. Discussion 
Telomerase is a complex holoenzyme, able to elongate telomere ends that have been 
shortened during successive cycles of cell division. Somatic cells lose about 25-200 telomeric 
nucleotides per cell division, unless telomeres reach a critical length and trigger replicative 
senescence or crisis. For immortal cells, the maintenance of telomeres length is essential and 
is provided by telomerase (Cong et al., 2002). Expression of hTERT gene, the limiting factor 
of telomerase activity, is usually absent in somatic cells, but present in the majority of cancer 
cells and immortalized cells (~90%) (Cong et al., 2002; Counter et al., 1995). Therefore, 
hTERT is one of the universal candidate genes in cancer research, and polymorphisms within 
hTERT gene or its regulatory elements may influence the personal risk of developing cancer.  
To date, two polymorphisms, located at the hTERT locus were found to modulate the risk of 
developing prostate cancer (Rafnar et al., 2009). For lung cancer 8 SNPs at 5p15.33 have 
been identified in several GWAS. Besides SNPs, some variable non-coding miniatellites like 
the VNTR MNS16A are located within the region of hTERT and may influence lung cancer 
risk (Baird, 2010). MNS16A is sited downstream of hTERT within a promoter region for an 
hTERT antisense transcript and comprises binding sites for transcription factor GATA1. Its 
number of tandem repeats was shown to modulate the promoter activity, alter the level of 
antisense transcript and therefore potentially alter the hTERT expression level. Several 
GWAS, conducted in diverse ethnicities, considered associations between the risk of 
developing cancer and MNS16A variants (Baird, 2010).  
The present diploma thesis investigated associations between MNS16A in the context of 
prostate cancer and lung cancer in an Austrian population. Furthermore a novel MNS16A 
variant, VNTR-212, was identified. 
MNS16A variants were for the first time investigated as a potential biomarker for the risk of 
developing prostate cancer. One major advantage of this study set up was, that the control 
group underwent biopsy of the prostate and was therefore known to be free of prostate cancer. 
Prostate cancer cases were histologically confirmed. Controls were diagnosed with BPH, an 
enlargement of the prostate, which is not considered as precursor to cancer (Kristal et al., 
2010). Between 70% to 80% of men in their 7th to 8th life decade show indication of BPH, 
wherefore it is hardly achievable to find a male control population without prostate 
alterations, at least in this age group (Berry et al., 1984). Moreover this study encompassed a 
large number (1137) of prostate cancer patients, which is the third highest number of cases in 
all published sudies on MNS16A variants so far. Another positive issue of our study design 
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was the successful genotyping of MNS16A variants, with 98.1% genotyping efficiency of 
prostate cancer samples and 98.6% genotyping efficiency of lung cancer samples.  
The initial aim of the study was to identify a genetic biomarker, which enables to differentiate 
between aggressive and indolent forms of prostate cancer. Currently the common treatment of 
advanced prostate cancer is radical prostatectomy, external beam radiation therapy (with and 
without hormonal therapy) and primary androgen deprivation (Ponholzer et al., 2011). 
However, the majority of prostate cancer cases are indolent and would not require radical 
treatment, which is often accompanied by harmful side effects (Tosoian and Loeb, 2010). 
Anyway, no significant associations were observed in the stratified analysis of patients with 
Gleason score 2-6 and 7-10  However, our study revealed a significant association between 
MNS16A VNTR-274 and a diminished risk to develop prostate cancer at least in men ≥70 
years (OR=0.09). MNS16A VNTR-274 may therefore be utilized as a biomarker for prostate 
cancer risk assessment in men ≥70 years.  
Another aim was the investigation of  MNS16A alleles as a potential biomarker for the risk of 
developing lung cancer in our Caucasian study population. The lung cancer study population 
comprised 665 lung cancer cases, which is rather small compared to other MNS16A surveys. 
A strength of our control group was, that it comprised a population-based as well as a 
hospital-based subgroup. Three studies on MNS16A alleles and risk of lung cancer or lung 
cancer survival were published so far. The very first association study on MNS16A was made 
in the context of lung cancer by L. Wang et al. in a Texan study population (79% ≥ 60 years) 
in 2003. The Texan study was rather preliminary and suboptimal, with a small hospital-based 
study-population, comprising 53 NSCLC patients and 72 cancer-free controls. Moreover, 
Wang et al. isolated genomic DNA from blood cells as well as from the tumor samples of the 
NSCLC patients. Their investigations obtained no significant results, but a tendency towards 
the LL genotype as risk factor was observed (Wang et al., 2003). This trend is in accordance 
with the significant associations we observed for the NSCLC patients ≥70 years. This diploma 
thesis demonstrated, that, single VNTR-243, genotype 243/302 and SL and SS+SL genotypes 
were associated with a reduced risk of NSCLC in patients of 70 years and above. Wang et al. 
published another study on MNS16A alleles affecting the survival duration of patients with 
NSCLC in 2010. The hospital-based, Texan study population comprised 808 NSCLC patients. 
The aforementioned authors showed that the SS genotype was associated with a shorter 
survival time (OR=2.34) compared to the LL genotype among 221 NSCLC patients stage I 
and II. These findings were not evident in the overall study-population(Wang et al., 2010). So 
far, this thesis did not consider associations of MNS16A alleles and the survival of lung 
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cancer, but they may be involved in subsequent studies, for which this study is a heplful 
prerequisite. The most recent study on MNS16A variants and lung cancer risk was conducted 
in a Korean study-population in 2010 by Jin et al.. The study-population consisted of 937 lung 
cancer patients, 703 NSCLC patients and 943 healthy controls. They demonstrated that 
NSCLC patients with genotypes comprising at least one VNTR-243 were significantly 
associated with a better overall survival duration compared to genotypes without VNTR-243. 
On the other hand, single VNTR-243 and genotype 243/302 were identified as risk markers 
for lung cancer onset (Jin et al., 2011). In the current study, the single VNTR-243 and the 
genotype 243/302 were also found to be associated with an increased lung cancer risk, in 
subjects ≤55 years. Furthermore, this survey was able to demonstrated, that genotype 274/302 
(containing the other short allele) and SL and SL+SS genotypes were associated with an 
increased lung cancer risk in patients ≤55 years. Jin et al.`s study population is rather young 
(61.7+- 9.2 years) and may therefore be comparable with our study population ≤55 years. 
Considering the similar age distribution, equal results are even more indicative. VNTR-243 
may be a potential genetic biomarker for lung cancer risk at an early age, at least in Caucasian 
and Korean populations. Since the 5-year survival rate for lung cancer is poor and early 
detection of lung cancer is therefore crucial for a better prognosis (Petersen, 2011), the 
identification of genetic risk factors may help to develop an improved risk assessment. 
 
Besides lung cancer, MNS16A variants were also investigated as a possible biomarker in the 
context of several other cancer sites. In 2007, a study on MNS16A variants, the occurrence of 
malignant gliomas and the survival time of glioma patients was published. The study 
population consisted of 352 Caucasian patients with glioblastoma or anaplastic gliomas and 
302 volunteer controls. No associations between MNS16A genotypes and the survival time 
were observed, however the SS genotype was significantly overrepresented in patients, when 
the LL genotype was taken as reference (Carpentier et al., 2007). In 2008, results from a study 
on MNS16A, conducted in a Chinese study-population, comprising 1029 breast cancer cases 
and 1107 matching controls, were presented. A significantly elevated risk of developing 
breast cancer was observed for the genotypes 274/302, 243/302 and 243/243 when compared 
to the wild-type genotype. Furthermore, it was reported, that the genotype 274/302 was 
associated with a significant increase in axillary lymph nodes metastasis (Wang et al., 2008c). 
A survey in 2009 compared the MNS16A genotype distribution of 1391 glioma and 
meningnoma patients with 1359 population based controls and did not detect an association 
between MNS16A alleles and the risk of glioma. Anyways, a significantly better survival in 
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glioma patients, carrying the LL genotype, compared to patients carrying the SL or SS 
genotype was observed (Andersson et al., 2009). In 2011, our group conducted a study based 
on 90 colorectal cancer patients, 308 patients with high-risk polyps, 1022 patients with low-
risk polyps and 1822 cancer- and polyp free controls (all Caucasians) and showed that the 
VNTR-274 significantly increased the risk of developing colorectal cancer, Furthermore, a 
novel MNS16A variant, VNTR-364, was identified (Hofer et al., 2011). In the course of the 
present study another novel MNS16A allele, the short VNTR-212, was identified. Also in 
2011, a Chinese study on MNS16A variants and the risk of nasopharyngeal cancer, based on 
855 Chinese patients and 1036 matching controls was published. It concluded, that subjects 
carrying the S-allele had a significantly reduced risk of nasopharyngeal cancer, compared to 
the LL-genotype carrier (Zhang et al., 2011). So far, studies on MNS16A as cancer biomarker 
yielded in opposing results, since cancer type and characteristics of the study populations 
varies among them.  
To establish MNS16A variants as biomarker for prostate cancer and lung cancer, further 
confirmation in larger cohorts and various ethnicities are required.  
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